Skip to search formSkip to main contentSkip to account menu

NOV 002

Known as: NOV-002, NOV002, Oxidized Glutathione NOV-002 
A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

CisplatinDrug CombinationsGlutathione Disulfide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Possible modulating impact of glutathione disulfide mimetic on physiological changes in irradiated rats
Glutathione disulfide mimetic (NOV-002) is a complex of oxidized glutathione (GSSG) formulated with cisplatin at approximately… 
2013
2013
NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis
Metastasis is the major cause of death in cancer. Most therapies currently in the clinic aim to eradicate primary tumor, but do… 
2011
2011
Letter to the editor regarding the article by Jenderny et al.
2010
2010
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung…
LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance… 
2010
2010
Abstract 1615: The redox modulator NOV-002 inhibits proliferation of ovarian tumor cells but increases proliferation of myeloid cells
Clinical trials in solid tumor indications have shown that NOV-002 (a formulation of glutathione disulfide) combined with… 
2010
2010
Abstract 430: Serpin-A1 and A3 as potential pharmacodynamic biomarkers for NOV-002, a redox-modulating anti-cancer agent
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC NOV-002 is a formulation of disodium glutathione… 
2010
2010
Collaborative Undergraduate HBCU Student Summer Prostate Cancer Training Program
Abstract : There is a critical need to increase the number of racially and ethnically diverse prostate cancer researchers. The… 
2010
2010
Abstract P1-11-05: Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with…
Background: NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell… 
2009
2009
Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and…
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2141 Background: Chemotherapy induced anemia is a… 
Review
2008
Review
2008
NOV-002, a mimetic of glutathione disulfide
Background: Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)